Amifostine Protects Against Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma | Zendy

Maryam Fouladi | Zendy; Murali Chintagumpala | Zendy; David M. Ashley | Zendy; Stewart J. Kellie | Zendy; Sridharan Gururangan | Zendy; Tim Hassall | Zendy; Lindsey Gronewold | Zendy; Clinton F. Stewart | Zendy; Dana Wallace | Zendy; Alberto Broniscer | Zendy; Gregory A. Hale | Zendy; Kimberly A. Kasow | Zendy; Thomas E. Merchant | Zendy; B. Morris | Zendy; Matthew J. Krasin | Zendy; Larry E. Kun | Zendy; James M. Boyett | Zendy; Amar Gajjar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Amifostine Protects Against Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma

Author(s) -

Maryam Fouladi,

Murali Chintagumpala,

David M. Ashley,

Stewart J. Kellie,

Sridharan Gururangan,

Tim Hassall,

Lindsey Gronewold,

Clinton F. Stewart,

Dana Wallace,

Alberto Broniscer,

Gregory A. Hale,

Kimberly A. Kasow,

Thomas E. Merchant,

B. Morris,

Matthew J. Krasin,

Larry E. Kun,

James M. Boyett,

Amar Gajjar

Publication year - 2008

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2007.14.3974

Subject(s) - amifostine , ototoxicity , medicine , medulloblastoma , cisplatin , oncology , toxicity , chemotherapy , cancer research

To determine the role of amifostine as a protectant against cisplatin-induced ototoxicity in patients with average-risk (AR) medulloblastoma treated with craniospinal radiotherapy and four cycles of cisplatin-based, dose-intense chemotherapy and stem-cell rescue.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research